Lilly Phase III Candidate Meets Primary Endpoint of NSCLC Overall Survival Genetic Engineering News Enzastaurin reportedly failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of DLBCL relapse following rituximab-based chemotherapy. To enjoy more articles like this from GEN, click ... |
